Enhancement of cellular and humoral immune responses of HBV DNA vaccine by HSP70 and gp96.
- Author:
Yanzhong WANG
1
;
Saifeng WANG
;
Xiaojun ZHANG
;
Yang LI
;
Shiyu ZHAO
;
Songdong MENG
Author Information
1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
- Publication Type:Journal Article
- MeSH:
Adjuvants, Immunologic;
pharmacology;
Animals;
Female;
HSP70 Heat-Shock Proteins;
immunology;
Hepatitis B Core Antigens;
immunology;
Hepatitis B Surface Antigens;
immunology;
Hepatitis B Vaccines;
immunology;
Hepatitis B virus;
immunology;
Hepatitis B, Chronic;
immunology;
therapy;
Humans;
Immunoglobulin G;
immunology;
Membrane Glycoproteins;
immunology;
Mice;
Mice, Inbred BALB C;
T-Lymphocytes;
immunology;
Vaccines, DNA;
immunology
- From:
Chinese Journal of Biotechnology
2011;27(5):790-798
- CountryChina
- Language:Chinese
-
Abstract:
While currently therapeutic vaccines for chronic hepatitis B virus (HBV) infection are actively being developed to complement standard antiviral treatments, their immune activity, especially T cell activity, remains to be further improved. Here, we investigated the role of heat shock proteins HSP70 and gp96 on cellular and humoral immunity, using the main structure antigens of hepatitis core (HBcAg) and surface (HBsAg) as the DNA vaccine. By ELISPOT (enzyme linked immunospot assay), IFN-gamma intracellular staining, [3H]-thymidine incorporation and ELISA (enzyme linked immunosorbent assay) analyses, we showed that immunization with HBsAg/HBcAg DNA formulation along with HSP70 or gp96 induced significant increase of T-cell (about 1-6-fold) and antibody (about 20%-60%) immunity against HBsAg and HBcAg. These results may provide bases for designing HSP70- and gp96-based vaccines aimed at eliciting T-cell responses for therapeutic applications.
